PDF(Pubmed)
Abstract：
UNASSIGNED: Meningiomas, a common neoplasm of the central nervous system, is a widely studied meningeal tumor. According to the World Health Organization (WHO) 2021 classification of meningiomas, there are 15 subtypes that have been grouped into grades 1, 2, and 3. The WHO grade 1 meningiomas are generally grouped as benign while the WHO grades 2 and 3 tumors are grouped as malignant. Progesterone receptors and P63 are common immunohistochemical markers that have proven useful in the diagnosis, grading, and prognostication of many neoplasms such as breast carcinoma, prostate carcinoma, and gastrointestinal tumors in histopathology practice. The application of these immunohistochemical markers to the grading of meningiomas has been reported and their usefulness documented in reports from Africa, Europe, North America, South America, and Asia. This study, therefore, seeks to determine if these findings are applicable to the meningiomas seen in an African population.
UNASSIGNED: A 10-year review of results and histologically diagnosed cases of meningiomas received in the Department of Morbid Anatomy, University of Nigeria, Enugu. Immunostaining for progesterone receptors (PgRs) and P63 were done and results compared with histologic grades.
UNASSIGNED: The three WHO grades of meningioma were assessed in this study. M: F ratio was 1:1.4 and peak age was 41-50 years age range (SD ± 16.54). The majority of the cases were WHO grade 1 (86.1%) while the WHO grades 2 and 3 tumors were 8% and 5.9%, respectively. The fibrous variant was the most common subtype (27.1%). There was no correlation between progesterone receptor and P63 immunopositivity to the WHO grades of meningioma (P = 0.112 and P = 0.138, respectively).
UNASSIGNED: Our study showed that progesterone receptors and P63 immunopositivity did not correlate with the WHO grades of meningiomas. This may be due to the predominant variant of meningioma seen in this study. These findings indicate that PgR antagonist may not be an effective alternative for treatment in patients with inoperable meningiomas. Furthermore, P63 immunopositivity may not be a sufficient grading tool for managing meningiomas in our population.
UNASSIGNED: A 10-year review of results and histologically diagnosed cases of meningiomas received in the Department of Morbid Anatomy, University of Nigeria, Enugu. Immunostaining for progesterone receptors (PgRs) and P63 were done and results compared with histologic grades.
UNASSIGNED: The three WHO grades of meningioma were assessed in this study. M: F ratio was 1:1.4 and peak age was 41-50 years age range (SD ± 16.54). The majority of the cases were WHO grade 1 (86.1%) while the WHO grades 2 and 3 tumors were 8% and 5.9%, respectively. The fibrous variant was the most common subtype (27.1%). There was no correlation between progesterone receptor and P63 immunopositivity to the WHO grades of meningioma (P = 0.112 and P = 0.138, respectively).
UNASSIGNED: Our study showed that progesterone receptors and P63 immunopositivity did not correlate with the WHO grades of meningiomas. This may be due to the predominant variant of meningioma seen in this study. These findings indicate that PgR antagonist may not be an effective alternative for treatment in patients with inoperable meningiomas. Furthermore, P63 immunopositivity may not be a sufficient grading tool for managing meningiomas in our population.
摘要：
■脑膜瘤，一种常见的中枢神经系统肿瘤，是一种被广泛研究的脑膜肿瘤.根据世界卫生组织（WHO）2021年脑膜瘤分类，有15个亚型已分为1级，2级和3级。WHO1级脑膜瘤通常被归类为良性,而WHO2级和3级肿瘤被归类为恶性。孕激素受体和P63是常见的免疫组织化学标记，已被证明在诊断中有用，分级,和许多肿瘤如乳腺癌的预后，前列腺癌,和胃肠道肿瘤的组织病理学实践。已经报道了将这些免疫组织化学标记物应用于脑膜瘤的分级，并在非洲的报告中记录了它们的有用性，欧洲,北美,南美洲,和亚洲。这项研究,因此,试图确定这些发现是否适用于非洲人群中的脑膜瘤。
■对病态解剖学部门收到的脑膜瘤的结果和组织学诊断病例进行了10年审查，尼日利亚大学,埃努古.对孕激素受体（PgRs）和P63进行免疫染色，并将结果与组织学等级进行比较。
■在这项研究中评估了WHO三种级别的脑膜瘤。M：F比为1：1.4，峰值年龄为41-50岁（SD±16.54）。大多数病例为WHO1级（86.1％），而WHO2级和3级肿瘤分别为8％和5.9％，分别。纤维变体是最常见的亚型(27.1%)。孕激素受体和P63免疫阳性与脑膜瘤的WHO等级之间没有相关性（分别为P=0.112和P=0.138）。
■我们的研究表明，孕激素受体和P63免疫阳性与脑膜瘤的WHO等级无关。这可能是由于在本研究中看到的脑膜瘤的主要变异。这些发现表明，PgR拮抗剂可能不是无法手术的脑膜瘤患者的有效替代治疗方法。此外，P63免疫阳性可能不是管理我们人群脑膜瘤的足够分级工具。
■对病态解剖学部门收到的脑膜瘤的结果和组织学诊断病例进行了10年审查，尼日利亚大学,埃努古.对孕激素受体（PgRs）和P63进行免疫染色，并将结果与组织学等级进行比较。
■在这项研究中评估了WHO三种级别的脑膜瘤。M：F比为1：1.4，峰值年龄为41-50岁（SD±16.54）。大多数病例为WHO1级（86.1％），而WHO2级和3级肿瘤分别为8％和5.9％，分别。纤维变体是最常见的亚型(27.1%)。孕激素受体和P63免疫阳性与脑膜瘤的WHO等级之间没有相关性（分别为P=0.112和P=0.138）。
■我们的研究表明，孕激素受体和P63免疫阳性与脑膜瘤的WHO等级无关。这可能是由于在本研究中看到的脑膜瘤的主要变异。这些发现表明，PgR拮抗剂可能不是无法手术的脑膜瘤患者的有效替代治疗方法。此外，P63免疫阳性可能不是管理我们人群脑膜瘤的足够分级工具。
